Direct renin inhibitors

Blockers, direct renin inhibitors, central o -agonists, peripheral adrenergic antagonists, and direct arterial vasodilators are alternatives that may be used in select patients after primary agents (Table 10-3). 

ACE inhibitors, ARBs, and direct renin inhibitors are contraindicated in sexually active girls because of potential teratogenic effect and in those who might have bilateral renal artery stenosis or unilateral stenosis in a solitary kidney. 

Chronic hypertension is defined as elevated BP that was noted before pregnancy began. Methyldopa is considered the drug of choice because of experience with its use. /3-Blockers, labetalol, and CCBs are also reasonable alternatives. ACE inhibitors and ARBs are known teratogens and are absolutely contraindicated. The direct renin inhibitor aliskiren also should not be used in pregnancy. 

Aliskiren (Tekturna) [Direct Renin Inhibitor] WARNING May... 

Ram CV. Direct renin inhibitors a new approach to antihypertensive drug treatment. J Cfin Hypertens (Greenwich) 2007 9(8) 615-21. 

Data from Uresin Y et al Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007 8 190.)... 

Aliskiren (oral) Direct renin inhibitor, inhibits the RAAS HF, post MI, diabetic Side effects include... 

An alternative option for the treatment of hypertension was pursued with direct renin inhibitors. [21 ] Monoclonal antibodies, directed against renin, had shown blood pressure lowering properties in animal models. However, due to their immunogenicity and mandatory parenteral administration, they proved not suitable for long term treatment. 

Aliskiren (Rasile, Tekturna ) is the first direct renin inhibitor, which was brought on to the market by Novartis in 2007 for the treatment ofessentiaihypertension. 

Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh C-M, Bizot M-N, Dieterich HA, Howard D, Dole WP (2008) Pharmacokinetics of the oral direct renin inhibitor Aliskiren in combination with digoxin, atorvastatin, and ketocona-zole in healthy subjects The role of P-glycoprotein in the disposition of Aliskiren. J Clin Pharmacol 48 1323-1338. 

DIRECT RENIN INHIBITORS [SEDA-31, 360 SEDA-32, 388 SEDA-33, 420]... 

White WB, Bresaher R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, Chang W, Keefe DL. Safety and tolerability of the direct renin inhibitor ahskiren a pooled analysis of clinical experience in more than 12,000 patients with hypertension. J Clin Hypertens (Greenwich) 2010 12(10) 765-75. 

Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Long-term safety, tolerabihty, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension. Hypertens Res 2009 32(3) 169 75. 

Gradman AH, Weir MR, Wright M, Bush CA, Keefe DL. Efficacy, safety and tolerabihty of aliskiren, a direct renin inhibitor, in women with hypertension a pooled analysis of eight studies. J Hum Hypertens 2010 24(11) 721-9. 

Sanoski CA. Aliskiren an oral direct renin inhibitor for the treatment of hypertension. Pharmacotherapy 2009 29(2) 193-212. 

Ayalasomayajula S, Yeh CM, Vaidyanathan S, Flannery B, Dieterich HA, Howard D, Bedigian MP, Dole WP. Effects of aliskiren, a direct renin inhibitor, on cardiac repolarization and conduction in healthy subjects. J Clin Pharmacol 2008 48(7) 799-811. 

Vaidyanathan S, Bartlett M, Dieterich HA, Yeh CM, Antunes A, Howard D, Dole WP. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosor-bide-5-mononitrate in healthy subjects. Car-diovasc Ther 2008 26(4) 238 6. 

DIRECT RENIN INHIBITORS fSEDA-33, 420 SEDA-34, 328 SEDA-35, 373]... 

---